NEWS

Homology Medicines Announces Pricing of Initial Public Offering
March 27, 2018

BEDFORD, Mass. – Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today the pricing of its initial public offering of 9,000,000 shares of common stock at a public offering price of $16.00 per share, before underwriting discounts and commissions. All of the common stock is being offered by Homology. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 1,350,000 shares of common stock from the Company at the initial public offering price, less the underwriting discounts and commissions. The Company’s common stock is expected to begin trading on the Nasdaq Global Select Market on March 28, 2018 under the ticker symbol “FIXX.”

BofA Merrill Lynch, Cowen and Evercore ISI are acting as joint book-running managers for the offering. BTIG is acting as the lead manager for the offering.

A registration statement relating to the securities being sold in the offering has been declared effective by the Securities and Exchange Commission. This offering is being made only by means of a prospectus. Copies of the final prospectus relating to this offering may be obtained, when available, by contacting: BofA Merrill Lynch, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, Attention: Prospectus Department, or by email at dg.prospectus_requests@baml.com; Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY 11717, Attention: Prospectus Department, or by phone at (631) 274-2806; or Evercore ISI, Attention: Equity Capital Markets, 55 East 52nd Street, 36th Floor, New York, NY 10055, by phone at (888) 474-0200, or by email at ecm.prospectus@evercore.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.

Theresa McNeely
SVP, Corporate Communications & Patient Advocacy
tmcneely@homologymedicines.com
508-523-9511